My ePortfolio Register   

Neratinib in HER2 or HER3 mutant solid tumours

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.04.17
Views: 1104

Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Hyman speaks with ecancer at AACR 2017 to discuss results of the phase II SUMMIT trial of neratinib, which you can read more about here, or watch the press conference in which these results were presented.

He describes the response of patients with HER2 mutations to neratinib, most notably in breast, cervical and biliary cancers, and considers the influence of tumour type and specific mutation to explain the lack of responses in patients with HER3 mutations and HER2 colorectal tumours.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence